In this file photo taken on April 08, 2020, one vial of the drug remdesivir lies during a press conference about the start of a study with the Ebola drug remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, amid the new coronavirus COVID-19 pandemic. (Photo by AFP)
The European Commission, the bloc's executive arm, on Friday authorized the use of anti-viral drug remdesivir to treat the new coronavirus.
"Today's authorization of a first medicine to treat COVID-19 is an important step forward in the fight against this virus," EU Health Commissioner Stella Kyriakides said in a statement.
"We are granting this authorization less than a month after the application was submitted, showing clearly the EU's determination to respond quickly whenever new treatments become available," she said.
At least two major US studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.
Washington authorized the emergency use of the medicine -- which was originally intended as a treatment for Ebola -- on May 1, followed by several Asian nations including Japan and South Korea.
The green light comes on the recommendation of the European Medicines Agency which gave its conditional authorization last week for the treatment of patients above 12 years of age who are suffering pneumonia and require extra oxygen.
It said its assessment was based mainly on data from a study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID).
The research, published in the leading journal the New England Journal of Medicine in May, showed that injections of remdesivir speeded patient recovery compared with a placebo.
On average it reduced patients' hospital stays from 15 days to 11.
More than 11.019 million people have been infected globally and more than 520,000 have died since the COVID-19 disease first emerged in China.
The World Health Organization (WHO) on June 26 warned about a "significant resurgence" of cases of the new coronavirus in nearly a dozen European nations, saying the risk of another outbreak has now become a “reality.”
WHO regional director for Europe Hans Henri Kluge said in a statement, “For weeks I have spoken about the risk of resurgence as countries adjust to measures.”
The European Commission, the bloc's executive arm, on Friday authorized the use of anti-viral drug remdesivir to treat the new coronavirus.
"Today's authorization of a first medicine to treat COVID-19 is an important step forward in the fight against this virus," EU Health Commissioner Stella Kyriakides said in a statement.
"We are granting this authorization less than a month after the application was submitted, showing clearly the EU's determination to respond quickly whenever new treatments become available," she said.
At least two major US studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.
Washington authorized the emergency use of the medicine -- which was originally intended as a treatment for Ebola -- on May 1, followed by several Asian nations including Japan and South Korea.
The green light comes on the recommendation of the European Medicines Agency which gave its conditional authorization last week for the treatment of patients above 12 years of age who are suffering pneumonia and require extra oxygen.
It said its assessment was based mainly on data from a study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID).
The research, published in the leading journal the New England Journal of Medicine in May, showed that injections of remdesivir speeded patient recovery compared with a placebo.
On average it reduced patients' hospital stays from 15 days to 11.
More than 11.019 million people have been infected globally and more than 520,000 have died since the COVID-19 disease first emerged in China.
The World Health Organization (WHO) on June 26 warned about a "significant resurgence" of cases of the new coronavirus in nearly a dozen European nations, saying the risk of another outbreak has now become a “reality.”
WHO regional director for Europe Hans Henri Kluge said in a statement, “For weeks I have spoken about the risk of resurgence as countries adjust to measures.”
Thank you for reaching out to us. We are happy to receive your opinion and request. If you need advert or sponsored post, We’re excited you’re considering advertising or sponsoring a post on our blog. Your support is what keeps us going. With the current trend, it’s very obvious content marketing is the way to go. Banner advertising and trying to get customers through Google Adwords may get you customers but it has been proven beyond doubt that Content Marketing has more lasting benefits.
We offer majorly two types of advertising:
1. Sponsored Posts: If you are really interested in publishing a sponsored post or a press release, video content, advertorial or any other kind of sponsored post, then you are at the right place.
WHAT KIND OF SPONSORED POSTS DO WE ACCEPT?
Generally, a sponsored post can be any of the following:
Press release
Advertorial
Video content
Article
Interview
This kind of post is usually written to promote you or your business. However, we do prefer posts that naturally flow with the site’s general content. This means we can also promote artists, songs, cosmetic products and things that you love of all products or services.
DURATION & BONUSES
Every sponsored article will remain live on the site as long as this website exists. The duration is indefinite! Again, we will share your post on our social media channels and our email subscribers too will get to read your article. You’re exposing your article to our: Twitter followers, Facebook fans and other social networks.
We will also try as much as possible to optimize your post for search engines as well.
Submission of Materials : Sponsored post should be well written in English language and all materials must be delivered via electronic medium. All sponsored posts must be delivered via electronic version, either on disk or e-mail on Microsoft Word unless otherwise noted.
PRICING
The price largely depends on if you’re writing the content or we’re to do that. But if your are writing the content, it is $60 per article.
2. Banner Advertising: We also offer banner advertising in various sizes and of course, our prices are flexible. you may choose to for the weekly rate or simply buy your desired number of impressions.
Technical Details And Pricing
Banner Size 300 X 250 pixels : Appears on the home page and below all pages on the site.
Banner Size 728 X 90 pixels: Appears on the top right Corner of the homepage and all pages on the site.
Large rectangle Banner Size (336x280) : Appears on the home page and below all pages on the site.
Small square (200x200) : Appears on the right side of the home page and all pages on the site.
Half page (300x600) : Appears on the right side of the home page and all pages on the site.
Portrait (300x1050) : Appears on the right side of the home page and all pages on the site.
Billboard (970x250) : Appears on the home page.
Submission of Materials : Banner ads can be in jpeg, jpg and gif format. All materials must be deliverd via electronic medium. All ads must be delivered via electronic version, either on disk or e-mail in the ordered pixel dimensions unless otherwise noted.
For advertising offers, send an email with your name,company, website, country and advert or sponsored post you want to appear on our website to advert @ alexa. ng
Normally, we should respond within 48 hours.